Sialidase May Serve As a Potential Biomarker of Proliferation, Migration and Prognosis in Melanoma

Overview

Journal World J Oncol

Specialty Oncology

Date 2022 Sep 21

PMID 36128592

Authors

Qiu Peng

Liang Gao

Hong Bing Cheng

Jin Sheng Wang

Jia Wang

Affiliations

Soon will be listed here.

Abstract

Background: Melanoma is a kind of malignant tumor with high mortality originating from melanocytes. It is urgent to find new molecular biomarkers for prognosis and new treatment methods for melanoma. As an important molecule of sialidase family, neuraminidase-1 () has been found to play an important role in regulating the occurrence and progression of tumors, but the role of in melanoma is not sure.

Methods: The expression level of in melanoma and normal tissues was evaluated by analyzing the expression data from ONCOMINE, UALCAN and GEPIA database. The mutation, copy number alteration and gene correlation of in melanoma were evaluated by analyzing the melanoma data from cBioPortal database The protein expression levels of NEU1 were further validated by immunohistochemical (IHC) staining data from The Human Protein Atlas database. The melanoma data in TIMER 2.0 database were used to analyze the correlation between expression and immune cell infiltration. The proliferative and migratory abilities of melanoma cells were examined by cell proliferation and migration assay and nude mice.

Results: We discovered that was highly expressed in melanoma samples compared with normal samples. The alteration frequency of in melanoma patients reached 18%, and most of them were "mutation" type. The expression of was positively correlated with the overall survival of patients with melanoma. The expression of was positively correlated with the expression of proliferation marker and epithelial-mesenchymal transition marker and negatively correlated with the expression of apoptosis marker and . Moreover, the expression level of was related to the infiltration of immune cells in melanoma. Knockdown of attenuated the proliferative and migratory abilities of melanoma cells, as well as tumor progression of melanoma cells.

Conclusions: These findings suggest that may play a key role in the development of melanoma and may be used as a prognostic target of melanoma.

Citing Articles

Neuraminidase-1 (NEU1): Biological Roles and Therapeutic Relevance in Human Disease.

Du J, Shui H, Chen R, Dong Y, Xiao C, Hu Y Curr Issues Mol Biol. 2024; 46(8):8031-8052.

PMID: 39194692 PMC: 11353077. DOI: 10.3390/cimb46080475.

Metabolic Signaling in Cancer Metastasis.

Krieg S, Fernandes S, Kolliopoulos C, Liu M, Fendt S Cancer Discov. 2024; 14(6):934-952.

PMID: 38592405 PMC: 7616057. DOI: 10.1158/2159-8290.CD-24-0174.

Sialylation: A Cloak for Tumors to Trick the Immune System in the Microenvironment.

Zhou X, Chi K, Zhang C, Liu Q, Yang G Biology (Basel). 2023; 12(6).

PMID: 37372117 PMC: 10294807. DOI: 10.3390/biology12060832.

Types of Cancer and Research Covered in .

Takabe K, Benesch M World J Oncol. 2023; 13(6):325-328.

PMID: 36660205 PMC: 9822687. DOI: 10.14740/wjon1558.

References

Kato T, Wang Y, Yamaguchi K, Milner C, Shineha R, Satomi S . Overexpression of lysosomal-type sialidase leads to suppression of metastasis associated with reversion of malignant phenotype in murine B16 melanoma cells. Int J Cancer. 2001; 92(6):797-804. DOI: 10.1002/ijc.1268. View

Hou G, Liu G, Yang Y, Li Y, Yuan S, Zhao L . Neuraminidase 1 (NEU1) promotes proliferation and migration as a diagnostic and prognostic biomarker of hepatocellular carcinoma. Oncotarget. 2016; 7(40):64957-64966. PMC: 5323129. DOI: 10.18632/oncotarget.11778. View

Lei F, Jin L, Liu X, Lai F, Yan X, Farrelly M . RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors. Cell Death Dis. 2018; 9(6):679. PMC: 5992182. DOI: 10.1038/s41419-018-0714-7. View

Rhodes D, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs B . Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007; 9(2):166-80. PMC: 1813932. DOI: 10.1593/neo.07112. View

Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam B . The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A. 2005; 102(17):6092-7. PMC: 1087936. DOI: 10.1073/pnas.0501564102. View

Ren L, Zhang L, Huang S, Zhu Y, Li W, Fang S . Effects of sialidase NEU1 siRNA on proliferation, apoptosis, and invasion in human ovarian cancer. Mol Cell Biochem. 2015; 411(1-2):213-9. DOI: 10.1007/s11010-015-2583-z. View

dAzzo A, Bonten E . Molecular mechanisms of pathogenesis in a glycosphingolipid and a glycoprotein storage disease. Biochem Soc Trans. 2010; 38(6):1453-7. PMC: 3129614. DOI: 10.1042/BST0381453. View

Ugurel S, Rohmel J, Ascierto P, Flaherty K, Grob J, Hauschild A . Survival of patients with advanced metastatic melanoma: The impact of novel therapies. Eur J Cancer. 2015; 53:125-34. DOI: 10.1016/j.ejca.2015.09.013. View

Uzdensky A, Demyanenko S, Bibov M . Signal transduction in human cutaneous melanoma and target drugs. Curr Cancer Drug Targets. 2013; 13(8):843-66. DOI: 10.2174/1568009611313080004. View

10.

Wang Z, Jensen M, Zenklusen J . A Practical Guide to The Cancer Genome Atlas (TCGA). Methods Mol Biol. 2016; 1418:111-41. DOI: 10.1007/978-1-4939-3578-9_6. View

11.

Pacheco I, Buzea C, Tron V . Towards new therapeutic approaches for malignant melanoma. Expert Rev Mol Med. 2011; 13:e33. DOI: 10.1017/S146239941100202X. View

12.

Monti E, Bonten E, dAzzo A, Bresciani R, Venerando B, Borsani G . Sialidases in vertebrates: a family of enzymes tailored for several cell functions. Adv Carbohydr Chem Biochem. 2010; 64:403-79. DOI: 10.1016/S0065-2318(10)64007-3. View

13.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

14.

Zheng X, Peng Q, Wang L, Zhang X, Huang L, Wang J . Serine/arginine-rich splicing factors: the bridge linking alternative splicing and cancer. Int J Biol Sci. 2020; 16(13):2442-2453. PMC: 7378643. DOI: 10.7150/ijbs.46751. View

15.

Arcidiacono P, Ragonese F, Stabile A, Pistilli A, Kuligina E, Rende M . Antitumor activity and expression profiles of genes induced by sulforaphane in human melanoma cells. Eur J Nutr. 2017; 57(7):2547-2569. PMC: 6182666. DOI: 10.1007/s00394-017-1527-7. View

16.

Talantov D, Mazumder A, Yu J, Briggs T, Jiang Y, Backus J . Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res. 2005; 11(20):7234-42. DOI: 10.1158/1078-0432.CCR-05-0683. View

17.

Abdulkhalek S, Amith S, Franchuk S, Jayanth P, Guo M, Finlay T . Neu1 sialidase and matrix metalloproteinase-9 cross-talk is essential for Toll-like receptor activation and cellular signaling. J Biol Chem. 2011; 286(42):36532-49. PMC: 3196117. DOI: 10.1074/jbc.M111.237578. View

18.

Wagle N, Emery C, Berger M, Davis M, Sawyer A, Pochanard P . Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011; 29(22):3085-96. PMC: 3157968. DOI: 10.1200/JCO.2010.33.2312. View

19.

Curti B, Faries M . Recent Advances in the Treatment of Melanoma. N Engl J Med. 2021; 384(23):2229-2240. DOI: 10.1056/NEJMra2034861. View

20.

Helgadottir H, Rocha Trocoli Drakensjo I, Girnita A . Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment. Front Oncol. 2018; 8:202. PMC: 6006716. DOI: 10.3389/fonc.2018.00202. View